Partnering Advantage

Progenra has discovered selective Molecular Glues and Small Molecules and identified development candidates for the treatment of inflammatory diseases and neurodegeneration.  Progenra is seeking industry partnerships for licensing opportunities surrounding the company’s Molecular Glue and Small Molecule portfolio, its proprietary UbiPro™ Drug Discovery Platform and its novel Molecular Glue Programs.

• Additionally, the Progenra Discovery Network, established through partnerships with CROs and academic experts, enhances Progenra’s development offerings to industry partners.
• Progenra is focused solely on the ubiquitin proteasome system, with its comprehensive ubiquitin proteasome system toolbox.
• The combination of Progenra’s unique technology and expertise provides insight into novel drug targets, affording a strategic timing advantage in partners’ therapeutic areas of interest.

Please contact Progenra Business Development for inquiries: bd@progenra.com